ClinicalTrials.gg
Enrolling by invitationNCT06145555Updated Nov 4, 2026

Acute Psychological Sleep Stabilisation for Patients Hospitalised With Depression

An interventional study of Acute psychological sleep stabilization and Sleep hygiene education in Insomnia and Depression, sponsored by Karolinska Institutet. Enrolling by invitation at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Sleep Initiation and Maintenance Disorders by Karolinska Institutet — 3 open to participants now, 3 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Karolinska Institutet.

Planned enrollment
13th of 23
100 · median 119
Started
2025
with 1 other
No phase
19 of 24
2 open now
Registered
22nd of 24
by date

Among the 24 studies in Sleep Initiation and Maintenance Disorders by Karolinska Institutet, this one is the 13th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2025, is one of 19 with no phase, and was the 22nd registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

3 of the 24 studies in Sleep Initiation and Maintenance Disorders by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Sleep Initiation and Maintenance Disorders by Karolinska Institutet, or all of them as a file.
02

Study summary

Disturbed sleep occurs in almost all patients in psychiatric inpatient care, and although it is well known that comorbid sleep disorders in depression often persist after treatment of depression and also increase the risk of new depressive episodes, the availability of effective, evidence-based treatments for sleep disorders in hospitalised patients is very limited.

The overall goal of the current project is to translate, adapt and evaluate an acute psychological sleep treatment based on cognitive behavioural therapy for insomnia (CBT-I) for patients hospitalized with depression and comorbid sleep problems in the specialized psychiatric inpatient care in the Stockholm Region. The main hypothesis for the study is that acute psychological sleep stabilization (APS) reduces self-reported sleep complains compared to care as usual reinforced with sleep hygiene advice, and secondary hypotheses are that APS also leads to reduced depressive symptoms and earlier discharge.

The project includes a pilot study, which will be followed by a randomized, controlled trial of APS compared to care as usual with structured sleep hygiene (minimal active control) and treatment effect is evaluated every three days during the hospital stay and 1,2,4 and 12 weeks after randomization. APS will be performed by existing staff in the department with the support of a psychologist.

03

Conditions studied

  • Insomnia
  • Depression

Keywords

  • CBT
  • Psychiatry
  • Inpatient care
  • Sleep
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted to the psychiatric inpatient care (Psykiatri Sydväst)
  • Depressive symptoms / confirmed depressive episode (uni- or bipolar)
  • Reports or is observed to have sleep problems in the form of insomnia, hypersomnia or delayed circadian phase
  • Knowledge of Swedish or English that is deemed sufficient to undergo the treatment
  • Consent to be included in the study and is judged to have understood what the study entails (care according to the Compulsory Psychiatric Care Act is not in itself an exclusion criterion)

Exclusion criteria

Exclusion Criteria:

  • Dementia
  • Intellectual disability
  • Severe somatic comorbidity with \<6 months
  • Ongoing mania / mixed-state
  • Complex problems that make APS impossible or inappropriate
  • Expected discharge within 3 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Acute psychological sleep stabilization

    The basis of the treatment is CBT-I adapted to a short version performed by trained staff (nurses or mental health care assistants) together with a psychologist. The manuals are designed to be read by patients and staff together and each treatment manual covers a specific topic. The focus of the treatment is behavioral changes and central manuals are stimulus control and scheduled sleep and sleep compression (if needed).

    Behavioral: Acute psychological sleep stabilization

  • Active comparator
    Sleep hygiene education

    The control treatment is delivered through structured manuals which patients work through together with the staff. The manuals cover sleep hindering factors (eg coffee, nicotine), sleep promoting factors (eg physical activity during the day, relaxation, blinds), sleep aids (for example, weight blanket, calm music).

    Behavioral: Sleep hygiene education

Interventions

  • BehavioralAcute psychological sleep stabilization

    See above (arm description)

  • BehavioralSleep hygiene education

    See above (arm description)

06

What researchers measure

Primary outcomes

  1. Insomnia Severity Index

    A self-report measure of insomnia symptoms. 7-item, self-rated questionnaire measuring insomnia severity. Total score 0-28, higher score indicates more severe sleep problems.

    Time frame: 2 weeks post randomization (secondary timepoints include day 4, 7, 10 and week 4 and 12)

Secondary outcomes

  1. Patient Health Questionnaire (PHQ-9)

    Self-reported depressive symptoms. PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. Total score 0-27, higher score indicates more severe depressive symptoms.

    Time frame: Day 4, 7, 10 14 and week 4 and 12 post randomisation

  2. Generalised Anxiety Disorder 7-item scale (GAD-7)

    Self-reported anxiety symptoms. A seven-item instrument that is used to measure or assess the severity of generalised anxiety disorder/symptoms. Total score 0-27. Higher scores indicative of more severe problem.

    Time frame: Day 4, 7, 10 14 and week 4 and 12 post randomisation

  3. European Quality of Life 5 Dimensions scale (EQ-5D)

    Self-reported quality of life. An instrument which evaluates the generic quality of life developed in Europe and widely used. The scale comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

    Time frame: Week 2, 4 and 12 post randomisation

Other outcomes

  1. Sleep Diary

    Participants will report their bedtime, risetime, amount of sleep daily using a simplified version of a sleep diary. We will look at total sleep time, sleep efficiency, and timing of sleep.

    Time frame: 0-14 days post randomisation

  2. Actigraphy

    An actigraph is placed on the participant's arm for 2 weeks. It measures participants' arm-movements. An algorithm can be used to estimate sleep from movement data.Data from actigraphs will be reported and analysed

    Time frame: 0-14 days post randomisation

  3. Side effects of treatment

    Patients will be asked to report any side-effects of the treatment with an open question

    Time frame: Day 7 and 14 post randomisation

  4. Treatment Credibility Scale

    A five-item version of Credibility/Expectancy Questionnaire, total score ranging from 0-50. Higher scores indicative of higher credibility.

    Time frame: Day 4 post randomisation

07

Study locations

1 site
  • Psykiatri Sydväst, Karolinska Hospital Huddinge
    Stockholm, Sweden
08

References and documents

Individual participant data

Plan to share: No — Individual data will not be shared

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 21 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Nov 24, 2023
StartActual
Mar 7, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06145555
Collaborators
Region Stockholm
Responsible party
Sandra Tamm (M.D., PhD, Karolinska Institutet) — Principal investigator
First posted
Nov 24, 2023
Start date
Mar 7, 2025
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Sandra Tamm
principal investigator · Karolinska Institutet
Susanna Jernelöv
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion